TCT、高危型HPV检测筛查诊断宫颈癌及癌前病变的病理学对照研究

目的:研究液基薄层细胞学检测(Thinprep cytologic test,TCT)、高危型人乳头瘤状病毒(Human papillomavirus,HPV)检测筛查诊断宫颈癌及癌前病变的病理学对照.方法:回顾性分析2020年1月至2021年1月期间于我院进行宫颈癌筛查的127例女性患者临床资料,分别进行TCT、高危型HPV、宫颈组织检测.以病理学结果为金标准,对比TCT、高危型HPV检出率以及诊断准确度、灵敏度、特异度、阳性预测值、阴性预测值.结果:经检查127例进行宫颈癌筛查女性经宫颈活体组织检查确诊为宫颈病变者51例,其中LSIL19例、HISL32例;宫颈癌患者9例;其余67例未发现宫颈癌及癌前病变.TCT检出37例,检出率为61.67％;高危型HPV检出40例,检出率为66.67％,组间比较差异无统计学意义(P>0.05).TCT检测的灵敏度、特异度、准确度、阳性预测值、阳性预测值略低于高危型HPV检测,但组间比较差异无统计学意义((P>0.05).结论:TCT、高危型HPV检测在宫颈癌及癌前病变筛查中具有重要价值,临床可根据患者个人情况进行选择.     

高龄孕妇外周血胎儿游离DNA产前筛查胎儿常见非整倍体的临床应用研究

目的探讨高龄孕妇外周血胎儿游离DNA在产前筛查常见非整倍体中的应用价值。方法选取2012年2月～2018年2月于我院产科筛查常见染色体非整倍体的高龄孕妇500例,均采集10ml孕妇外周血对胎儿游离DNA进行提取,利用大规模平行测序技术(MPS)进行检测,分析13-三体、18-三体、21-三体的检出情况。以羊水染色体核型为金标准,评估外周血胎儿游离DNA在常见非整倍体中的筛查价值,并记录其诊断的敏感度、特异度、准确率、阳性预测值、阴性预测值。采用Kappa检验分析外周血胎儿游离DNA与羊水染色体核型诊断的一致性。结果在500例孕妇中,经孕妇外周血胎儿游离DNA筛查出46例(9.20%)阳性,阴性454例(90.80%)。胎儿游离DNA筛查13-三体的敏感度、特异度、准确率、阳性预测值、阴性预测值分别为80.00%、100.00%、99.80%、100.00%、99.80%,与羊水染色体核型的一致性Kappa检验值为0.888。胎儿游离DNA筛查18-三体的敏感度、特异度、准确率、阳性预测值、阴性预测值分别为87.50%、99.38%、99.00%、82.35%、99.59%,与羊水染色体核型的一致性Kappa检验值为0.843。胎儿游离DNA筛查21-三体的敏感度、特异度、准确率、阳性预测值、阴性预测值分别为95.83%、99.58%、99.40%、92.00%、99.79%,与羊水染色体核型的一致性Kappa检验值为0.936。胎儿游离DNA筛查非整倍数的敏感度、特异度、准确率、阳性预测值、阴性预测值分别为97.78%、99.56%、99.40%、95.65%、99.78%,与羊水染色体核型的一致性Kappa检验值为0.964。结论高龄孕妇外周血胎儿游离DNA产前筛查常见非整倍体的敏感度、特异度及准确率均较高,与羊水染色体核型诊断的一致性较好。     

超声检测早孕期胎儿NT在筛查DS中的临床应用价值

目的探讨超声检测早孕期胎儿NT在筛查DS中的临床应用价值。方法选取2019年01月至2020年06月在三亚市人民医院就诊的孕11～13w的2175例孕妇作为研究对象,均予超声检测胎儿NT厚度、无创产前基因检测技术进行DNA测序以及血清学检测β-HCG和PAPP-A,并对检测结果进行比较分析。随后对检测高危孕妇进行遗传咨询,且在知情同意下进行羊膜腔穿刺以确诊是否患有DS。结果超声联合基因检测技术筛查高危23例,确诊3例,敏感度100%,特异度99.18%,阳性预测值14.29%,阴性预测值100%;超声联合血清学筛查高危26例,确诊3例,敏感度100%,特异度98.95%,阳性预测值11.54%,阴性预测值100%;单一基因检测技术筛查高危32例,确诊2例,敏感度66.67%,特异度98.64%,阳性预测值6.25%,阴性预测值99.95%;单一血清学筛查高危27例,确诊1例,敏感度33.33%,特异度98.82%,阳性预测值3.70%,阴性预测值99.91%。其中,联合筛查的敏感度、阳性预测值明显高于单一基因检测和单一血清学检查,且可确定产妇患有DS的风险性。结论早孕期采用无创产前基因检测或血清学检测筛查DS时,联合超声检测其胎儿NT厚度,能提高早孕期DS的检出率,对降低出生缺陷有良好的临床应用价值。     

高危型人乳头瘤样病毒DNA检测在宫颈癌早期筛查探讨

目的探讨高危型人乳头瘤样病毒DNA检测在宫颈癌早期筛查的作用。方法选取2011年8月~2013年8月前来我院接受宫颈癌早期筛查的1000例患者为研究对象，回顾性分析其临床检验资料。结果人乳头瘤样病毒感染者142例，CINⅠ25例，CINⅡ18例，CINⅢ16例，癌细胞扩散者10例。以不典型鳞状上皮细胞、高度鳞状上皮内病变为分界点的敏感度、特异度、阳性预测值、阴性预测值均较高。结论高危型人乳头瘤病毒DNA检测在宫颈癌早期筛查的应用中，其敏感度和阴性预测值均较高，而其结合细胞学检查结果可有效的提升敏感度和阴性预测值，值得临床推广。     

ELISA法检测ら珠蛋白链在广西东南亚缺失型α-地中海贫血筛查中的应用价值

目的 评价并比较酶联免疫吸附试验(ELISA)法检测ら珠蛋白链与聚合酶链反应(PCR).方法 在诊断广西东南亚缺失型α-地中海贫血中的临床应用价值.方法 收集广西壮族自治区人民医院门诊部和产科住院病例210份血样标本(其中82例各型α-地中海贫血,13例各型α-地中海贫血,115例为正常对照;地中海贫血组均有MCV＜80fl、MCH＜27pg,Hb在25～128g/L之间,采用ELISA法和聚合酶链反应(PCR)方法进行检测,最后对ELISA法筛查--SEA携带者总的敏感度、特异度、准确度、阴性预测值、阳性预测值与聚合酶链反应(PCR)方法进行分析并比较其诊断--SEA携带者的临床应用价值.结果 ELISA法诊断--SEA携带者总的敏感度、特异度、准确度、阴性预测值和阳性预测值分别是96.2％、98.3％、97.6％、98.3％和96.2％,而聚合酶链反应(PCR)法检测的相应指标均为100.0％(P＞0.05),两者无显著性差异.尽管ELISA法对--SEA携带者有很高的检出率,但其检测α-地中海贫血时有明显的漏检率,尚不属于成熟检测方法,需要进一步研究变流.结论 ELISA法能很有效地检出--SEA携带者,加之该法简便快速、技术要求不高且经济实用,适用于常规实验室筛查.但从本次评价的结论看,该方法漏检率较高,还不适宜推广作为大规模筛查方法.     

浙江沿海地区宫颈病变患者中高危型HPV检测及其临床价值

目的 分析宫颈病变患者中高危型HPV的感染情况及特点,探讨HR-HPV DNA检测用于高级别宫颈上皮内瘤变中的价值.方法 回顾性分析采用液基薄层细胞学(TCT)检查、HR-HPV检测和阴道镜检查并行活检的官颈病变患者1130例临床资料.经病理组织学检查证实宫颈炎症448例,官颈上皮内瘤变Ⅰ级和(或)湿疣(CIN Ⅰ/HPV Ⅰ)212例,高级别官颈上皮内瘤变或官颈上皮内瘤变Ⅱ/Ⅲ级(C1NⅡ/Ⅲ)442例,宫颈浸润癌(均为鳞癌)28例.结果 1130例官颈病变患者中HR-HPV阳性率为65.84％(744/1130).细胞学异常者为862例,其中ASCUS356例、ASCH 84例、LSIL 216例、HSIL 184例、癌22例.病理学≥CINI/HPVI者682例,HR-HPV阳性率为78.59％(536/682).筛查≥CINⅡ病变TCT的灵敏度为88.94％,特异度为32.73％,阳性预测值为48.49％,阴性预测值为80.60％;HC-Ⅱ的灵敏度为90.21％,特异度为51.82％,阳性预测值为57.14％,阴性预测值为88.14％;两者联合的灵敏度为97.45％,特异度为22.42％,阳性预测值为47.22％,阴性预测值为92.50％.结论 HR-HPV在各年龄组宫颈病变患者中均有较高的感染率,随着宫颈病变程度的加深,HR-HPV的感染率逐步升高.HC-Ⅱ检测HR-HPV DNA是筛查宫颈上皮内瘤变可选用的方法.HR-HPV DNA检测是一种有效的ASCUS和LSIL的管理手段,有较高的灵敏度和阴性预测值.     

Luminex XMAP液相芯片技术检测人乳头瘤病毒基因型的应用评价

目的 评价Luminex XMAP液相芯片技术在HPV感染检测中的临床价值.方法 取宫颈组织标本231份和正常宫颈脱落细胞33份,采用液相芯片技术和杂交捕获Ⅱ(HC Ⅱ)对所有标本进行HPV DNA检测.比较两种方法检测结果,对不一致标本及HPV单一型感染标本进行基因测序.结果 两种方法检测结果一致性极好(Kappa=0.8889).根据液相芯片检测结果,HPV检出率为82.95%,不同基因型感染率从高到低依次为:HPV 16、52、58、18、11、31、6、39、33、56、70.其中117份单一型感染,102份多重感染.高危型感染占87.43%,低危型12.57%.以组织病理学为确诊标准,液相芯片和HCⅡ检测CINⅡ、CINⅢ和宫颈癌HPV DNA的灵敏度、特异度、阳性预测值、阴性预测值分别依次为:93.07%、87.88%、98.17%、64.44%和94.81%、87.88%、98.21%、70.73%.所有液相芯片检出的单一型经基因测序验证准确率为98.29%.结论 所选宫颈病变患者HPV感染的常见型别是16、52、58、18、11、31、6.Luminex XMAP液相芯片技术是HPV分型检测及大规模筛查的理想方法.     

TCT技术与HPV分型技术在子宫颈病变筛查中的应用价值

为探讨液基薄层细胞检测法（TCT）与人乳头状瘤病毒（HPV）分型检测在子宫颈病变筛查中的应用价值,对18534例妇科宫颈刷检标本进行TCT检测,其中257例标本采用导流杂交技术（FTH）检测HPV分型。结果表明,257例标本中,108例HPV病毒检测结果为阳性（阳性率42.1%）,包括93例高危亚型感染,15例低危亚型感染,20例感染两种以上HPV亚型,149例HPV为阴性（57.9%）。HPV是诱发女性宫颈癌及生殖器病变的主要病源。TCT检测技术联合HPV分型应用于宫颈癌早期防治以及确诊子宫颈病变具有着重要意义。     

宫颈细胞学筛查及高危型HPV检测与宫颈组织学改变的相关性研究

目的 探讨宫颈细胞学及高危型HPV检测结果与宫颈组织病变的相关性,提高宫颈病变早期诊断的敏感度和特异度.方法 将254例不孕患者宫颈细胞学及高危型HPV检测结果分为四组,A组:宫颈细胞学阳性、高危型HPV阳性:B组:宫颈细胞学阳性、高危型HPV阴性;C组:宫颈细胞学阴性、高危型HPV阳性;D组:宫颈细胞学阴性、高危型HPV阴性,回顾分析此四组检测数据与宫颈组织病理之间的关系;并分别回顾分析宫颈细胞学阳性及高危型HPV阳性与宫颈组织病理之间的关系,比较其敏感度和特异度.结果 A组宫颈CINⅡ级及以上的发现率显著高于B组(P＜0.01),A组、B组和C组的CIN Ⅰ级发现率无差异(P＞0.05);单一宫颈细胞学检测CINⅡ级及以上阳性的敏感度100.0％、特异度46.74％,串行高危型HPV检测后其敏感度97.22％、特异度87.16％.结论 不孕症患者乃至日常体检宫颈筛查仍首选宫颈细胞学检查,宫颈细胞学串行高危型HPV检查明显降低了宫颈病变的误诊率.     

太原地区404例女性HPV感染状况及基因分型统计分析

目的探讨太原地区女性人乳头瘤病毒(HPV)感染情况以及基因分型分布及特点。方法采用人乳头瘤病毒基因分型检测试剂盒(PCR技术及导流杂交技术)对太原地区404例女性进行21种HPV亚型分析。结果 404例检测者共检测到HPV阳性患者213例,阳性率为52.7%。21种HPV亚型(除HPV 42、43型外)均有检出,其中检出率较高的高危型有HPV 16(34.4%),HPV 58(13.4%),HPV 53(8.7%);检出率最高的低危型是HPV 6(2.2%)。阳性检出者中单一亚型感染占59.6%,多种亚型感染占40.4%;在多重感染中,伴随着合并感染的亚型数增加,比例逐渐下降。结论利用PCR技术和杂交技术检测女性HPV感染情况,对宫颈癌的早期诊断、预防及疗效观察具有重要的应用价值。     

Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA

Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evaluated the clinical performances of two new real-time PCR assays for detecting HR HPVs compared to that of the Hybrid Capture 2 test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott RealTime HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the criteria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate among the results for the three assays was 82.6%, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1% and 89.9% of cases, respectively. The two real-time PCR assays agreed with each other for 89.6% of the samples, and the concordance rate between them was equal to or greater than 98.0% for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6% with a specificity of 89.1% for detecting HR HPVs, while RealTime HR presented a sensitivity of 78.3% with a specificity of 99.2%. The sensitivity and specificity of Cobas HPV for detecting HR HPVs were 91.7% and 97.0%. The new real-time PCR assays exhibited lower sensitivities for detecting HR HPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of simultaneously identifying HPV types 16 and 18 from clinical samples.     

应用基因芯片诊断宫颈石蜡组织样本中人乳头状瘤病毒感染及其临床意义

目的探讨应用基因芯片检测宫颈石蜡组织标本中人乳头状瘤病毒（HPV）感染的可能性及其临床意义。方法收集解放军总医院诊断为宫颈鳞状上皮病变的石蜡组织标本40例,其中宫颈浸润性鳞癌18例,宫颈上皮内瘤变（CIN）Ⅲ12例,CINⅠ4例,CINⅡ6例。从组织中提取DNA后采用基因芯片检测23种常见HPV基因亚型,即PCR扩增后产物在基因芯片上进行杂交。同时选用10例经基因芯片检测16型和18型基因阳性的宫颈鳞癌的石蜡组织切片做原位杂交。基因芯片检测结果与部分原位杂交结果进行比较并分析。结果基因芯片检测的18例宫颈鳞癌HPV高危亚型均为阳性（100％）,其中1例为混合阳性;12例CINⅢ中11例为高危亚型阳性（91．7％）,1例阴性;6例CINⅡ的宫颈病变中高危型5例阳性,低危型1例阳性;4例CINⅠ中有2例低危型阳性、2例阴性;宫颈鳞癌和CINⅢ组与CINⅠ和Ⅱ组比较,差异有统计学意义（U=80．0,P〈0．01）。10例宫颈鳞癌基因芯片HPV16型和18型阳性组织中,原位杂交同型探针6例检测显示阳性。结论HPV基因芯片技术可用于检测多种亚型,特异性强,敏感性高,对HPV感染亚型的鉴别及宫颈癌的预防和治疗具有重要意义。     

Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques

One hundred and forty-eight randomly chosen neutral-buffered formaldehyde-fixed cervical biopsies in which cervical intra-epithelial neoplasia (CIN) I–III had been diagnosed were tested for HPV (human papilloma virus) DNA by in situ hybridization (ISH) and polymerase chain reaction (PCR). For ISH, we utilized a biotinylated panprobe and type-specific, genomic probe sets. For PCR, we used the general primers GP5/GP6 and their recently described, elongated version GP5+/GP6+, and included the modification of hot-start PCR. Amplified DNA was detected by gel electrophoresis and slot blot hybridization. The positivity rate of ISH was 59% for all biopsies and 69%, 62% and 46% for CIN I, II and III, respectively. The sensitivity of GP5/GP6 was 74% with cold-start PCR and 78% with hot-start PCR. When GP5+/GP6+ was used, the sensitivity increased to 89% with cold-start PCR and to 95% with hot-start PCR. Based on the most sensitive PCR technique, HPV detection was 93%, 95% and 96% in CIN I, II and III, respectively. The number of HPV types decreased with the severity of the lesion, and HPV 16 was the predominant type. Multiple HPVs were rare and almost all HPV-positive cases could be typed. ISH and slot blot hybridization correlated well regarding HPV typing specificity. Our results confirm that distinct HPV types are present in a high proportion of cases of CIN. The sensitivity of ISH is lower than that of PCR. Furthermore, the modified general primers GP5+/GP6+ give a higher yield than GP5/GP6, while hot-start PCR increases sensitivity even further.     

Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue

Archival paraffin-embedded tumor specimens offer a wealth of information for both cancer research and for routine clinical applications. However, the use of formalin-fixed, paraffin-embedded specimens for quantitative real-time PCR is not yet a standard diagnostic method in many laboratories, in particular for the quantification of human papillomavirus (HPV). Particularly high-risk HPV types are involved in almost 100% of the carcinogenesis of cervical cancer. We compared the diagnostic applicability and sensitivity of real-time PCR to that of chromogenic tyramide-signal-amplified in situ hybridization and conventional PCR for the detection of HPV from archival tissue in 164 cases of carcinoma in situ and cervical cancer. Furthermore, we examined whether the viral load of HPV is of prognostic relevance. Our findings indicate that patients in tumor stage I with a lower viral load of HPV type 16 (HPV16; up to 1,000 copies/ng of DNA) had a significantly better survival than HPV 16-negative patients (P = 0.037). We observed a greater sensitivity of both real-time PCR and conventional PCR for the detection of HPV16 and -18 compared to signal amplified in situ hybridization. We found a considerable concordance between HPV16 (kappa = 0.661) and HPV18 (kappa = 0.781) status as measured by real-time PCR and conventional PCR, indicating similar sensitivities. We recognized an inhibitory effect of formalin fixation and paraffin embedding on the evaluation of real-time PCR quantification.     

Analytical performance of a low-cost multiplex polymerase chain reaction human papillomavirus genotyping assay for use in Sub-Saharan Africa

We have tested a multiplex polymerase chain reaction (PCR) human papillomavirus (HPV) genotyping assay to fill the need for rapid and low-cost HPV detection in Sub-Saharan Africa. This method allows high throughput genotyping and simultaneous detection of 14 high-risk and two low-risk HPV types, by PCR amplification of HPV DNAs in a single reaction tube. In this study, we describe stepwise experiments to validate the multiplex HPV PCR assay for determination of HPV genotypes from 104 cervical brush samples from Tanzanian women. Assay performance was evaluated by determination of intra-laboratory reproducibility, sensitivity, and specificity. Further performance was assessed by comparison with the widely accepted and validated HPV My09/My11 amplification and hybridization assay. Statistics; the Cohen kappa (κ) and McNemar P values were used to analyze interobserver and intermethod agreement. Overall concordance between the multiplex and line blot hybridization assays was 99% (per sample) with a κ value equal to 0.95; and 96.49% (per detection event) with a κ value of 0.92. Interobserver reproducibility of the assay per sample was 95.76% with κ of 0.91. These results demonstrate that the multiplex HPV PCR assay has high analytical sensitivity and specificity in detecting as many as 16 different HPV genotypes and that its simplicity and low cost makes it well suited for sub-Saharan Africa.     

Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma

To evaluate a commercialized in situ hybridization (ISH) assay for detecting human papillomavirus (HPV) DNA, we compared the ability of a new ISH probe, Inform HPV III (Ventana Medical Systems, Tucson, AZ), to that of PCR assays to detect HPV DNA in cervical tissue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases; CIN 2, 28 cases; and CIN 3, 33 cases), and cervical carcinoma (29 cases). General HPV DNA was detected using consensus primer-mediated PCR assays. HPV genotyping was performed by using EasyChip HPV blot (King Car Yuan Shan Institute, I-Lan, Taiwan). HPV16 integration status (E2/E6 ratio) was determined by using quantitative real-time PCR. Our findings showed that the ISH and PCR had fair to good agreements in detecting HPV DNA across all CIN categories without significant differences (Kappa coefficient, 0.34 to 0.63; P = 0.13 to 1.0). However, ISH detected significantly fewer HPV-positive cases in carcinoma than PCR did (Kappa coefficient, 0.2; P = 0.03). Eleven cases with ISH⁻ PCR⁺ results had HPV types that can be detected by Inform HPV III. Five carcinoma cases with ISH⁻ PCR⁺ results showed a significantly higher level of integrated HPV16 (P = 0.008) than did the ISH⁺ cases. As a consequence, lower copy numbers of episomal HPV16 in carcinoma might be the cause for the false-negative ISH results. Although the punctate signal pattern of HPV significantly increased with the severity of disease (P trend = 0.01), no significant difference in the HPV16 integration status was observed between the cases with a punctate signal only and the cases with mixed punctate and diffuse signals (P = 0.4). In conclusion, ISH using the Inform HPV III probe seems comparable to PCR for detecting HPV DNA in cervical tissue with CINs. False-negative ISH results appear to be associated with the lower copy numbers of the episomal HPV16 but not with the ability of the Inform HPV III probe to detect specific HPV types. In addition, signal patterns, especially a mixed punctate and diffuse pattern of HPV, cannot be reliably used to predict viral integration status.     

Comparison between in situ hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia.

Integration of the human papillomavirus (HPV) genome is thought to be one of the causes of cancer progression. However, there is controversy concerning the physical status of HPV 16 in premalignant cervical lesions, and there have been no reports on the concordance between detection of the integrated form of HPV16 by real-time PCR and by in situ hybridization. We investigated specimens of cervical intraepithelial neoplasia (CIN) and invasive carcinomas for the physical status of HPV 16 by real-time PCR and in situ hybridization. The presence of the integrated form was detected by both real-time PCR and in situ hybridization in zero of four cases of CIN1, three of six cases of CIN2, nine of 27 cases of CIN3, and two of six cases of invasive carcinomas. Integrated HPV 16 was present in some premalignant lesions but was not always present in carcinomas. The concordance rate between the two methods for the detection of the presence of the integrated form was 37 of 43 (86%) cases. Real-time PCR and in situ hybridization were found to be complementary and convenient techniques for determining the physical status of the HPV genome. We conclude that a combination of both methods is a more reliable means of assessing the physical status of the HPV genome in cervical neoplasia.     

Detection of human papillomavirus DNA in cervical cancer tissue by the polymerase chain reaction

A method for detecting HPV DNA in cervical cancer tissue was developed without using isotopes. The DNA samples from the cancer tissues were first subjected to amplification by PCR, followed by polyacrylamide gel electrophoresis to identify the specific amplified fragment. The specificity and sensitivity of the PCR method are described. Compared with the dot hybridization technique, it is shown that the method is able to detect HPV DNA in cervical cancer tissues.     

高危型人乳头状瘤病毒和宫颈细胞学联合检测在诊断宫颈病变中的临床价值

目的 探讨高危型人乳头状瘤病毒(hish-risk human papillomavirus,HR-HPV)和宫颈细胞学联合检测在诊断宫颈病变中的临床价值.方法 对2004年10月至2006年12月北京大学第一医院就诊的患者进行HR-HPV检测和宫颈细胞学检查,对一项或两项结果异常者均行阴道镜下宫颈活检,并以宫颈活检结果为金标准,比较HR-HPV检测、宫颈细胞学检查、HR-HPV和宫颈细胞学联合检测对宫颈病变的诊断价值.结果 HR-HPV检测、宫颈细胞学检查及HR-HPV检测联合宫颈细胞学检查对诊断宫颈病变有不同价值.HR-HPV检测筛查CINⅡ、CINⅢ的敏感度、特异度、阳性预测值和阴性预测值分别为94.83%、31.06%、55.22%、87.02%,宫颈细胞学筛查CINⅡ、CINⅢ的敏感度、特异度、阳性预测值和阴性预测值分别为92.10%、31.06%、54.50%、81.43%,HR-HPV和宫颈细胞学联合检测筛查CINⅡ、CINⅢ的敏感度、特异度、阳性预测值和阴性预测值分别为99.65%、18.55%、61.46%、97.62%.结论 采用HR-HPV和宫颈细胞学联合检测可提高宫颈病变的检出率,并可指导临床医生对宫颈病变的治疗.